Assess MRI-targeted, systematic, or combined prostate biopsy for diagnosing prostate cancer to identify opportunities for diagnostic accuracy improvement.
This Institutional Review Board-approved, retrospective study, performed at a large, quaternary hospital, included all men undergoing prostate MRI (mpMRI) 1/1/2015-12/31/2019 with PSA ≥4 ng/mL, biopsy target on mpMRI (PI-RADS 3-5 lesion), and combined targeted/systematic biopsy ≤6 months post-MRI.